Mastrianni J A, Ingenito A J
J Pharmacol Exp Ther. 1987 Jul;242(1):378-87.
The relationship between the centrally mediated hypotensive and bradycardic effects of clonidine to central alpha-2 adrenergic receptor activation, brain beta-endorphin (BE) release and opiate receptor activation was studied in chloralose-anesthetized spontaneously hypertensive rats (SHRs) and Wistar-Kyoto rats, using a cerebroventricular perfusion system. Prior treatment of SHRs with i.v. naloxone (2 or 4 mg/kg) or i.c.v. yohimbine (10 or 20 micrograms/kg) reduced the hypotension and bradycardia induced by i.c.v. clonidine, but in Wistar-Kyoto rats naloxone had no similar blocking effects. Prazosin (20 micrograms/kg i.c.v.) reduced the clonidine bradycardia but not the hypotension in SHRs. Hypotension in the SHRs due to i.c.v. alpha-methylnorepinephrine (20 micrograms/kg) was reduced by both naloxone and yohimbine whereas alpha-methylnorepinephrine bradycardia was reduced by yohimbine but not by naloxone. Prior hypothalamic lesions in the SHRs reduced clonidine hypotension, but not bradycardia, and interfered with naloxone blockade of the residual clonidine hypotensive effect. Clonidine lowered immunoreactive BE levels in SHR hypothalamus, medulla and pituitary but did not change BE levels in the i.c.v. perfusate. The findings support the idea that in the SHRs, clonidine hypotension results from alpha-2 adrenergic stimulation of brain, causing BE release and central opiate receptor activation, and they suggest that the hypothalamus is involved in these interactions. Also, clonidine hypotension and bradycardia appear to involve different mechanisms in brain.
在使用脑室灌注系统的情况下,研究了可乐定的中枢介导的降压和减慢心率作用与中枢α-2肾上腺素能受体激活、脑β-内啡肽(BE)释放及阿片受体激活之间的关系,实验对象为水合氯醛麻醉的自发性高血压大鼠(SHRs)和Wistar-Kyoto大鼠。静脉注射纳洛酮(2或4mg/kg)或脑室内注射育亨宾(10或20μg/kg)预处理SHRs,可减轻脑室内注射可乐定引起的低血压和心动过缓,但在Wistar-Kyoto大鼠中,纳洛酮没有类似的阻断作用。哌唑嗪(20μg/kg脑室内注射)可减轻SHRs中可乐定引起的心动过缓,但不能减轻低血压。脑室内注射α-甲基去甲肾上腺素(20μg/kg)引起的SHRs低血压,可被纳洛酮和育亨宾两者减轻,而α-甲基去甲肾上腺素引起的心动过缓,可被育亨宾减轻,但不能被纳洛酮减轻。SHRs预先进行下丘脑损伤,可减轻可乐定引起的低血压,但不能减轻心动过缓,且干扰了纳洛酮对残余可乐定降压作用的阻断。可乐定降低了SHRs下丘脑、延髓和垂体中免疫反应性BE水平,但未改变脑室内灌注液中的BE水平。这些发现支持了以下观点:在SHRs中,可乐定引起的低血压是由脑内α-2肾上腺素能刺激导致BE释放和中枢阿片受体激活所致,并且提示下丘脑参与了这些相互作用。此外,可乐定引起的低血压和心动过缓在脑中似乎涉及不同的机制。